Intellia Therapeutics Inc (NASDAQ: NTLA)’s stock price has gone decline by -1.42 in comparison to its previous close of 21.81, however, the company has experienced a -13.83% decrease in its stock price over the last five trading days. The Motley Fool reported 2024-04-09 that These biotech stocks have missed out on market gains so far, falling in the double digits over the past year. But they are innovators with potential growth catalysts right around the corner.
Is It Worth Investing in Intellia Therapeutics Inc (NASDAQ: NTLA) Right Now?
The 36-month beta value for NTLA is at 1.84. Analysts have varying views on the stock, with 1 analysts rating it as a “buy,” 3 rating it as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for NTLA is 93.89M, and currently, shorts hold a 15.80% of that float. The average trading volume for NTLA on April 18, 2024 was 1.56M shares.
NTLA’s Market Performance
NTLA’s stock has seen a -13.83% decrease for the week, with a -21.45% drop in the past month and a -16.47% fall in the past quarter. The volatility ratio for the week is 4.82%, and the volatility levels for the past 30 days are at 4.23% for Intellia Therapeutics Inc The simple moving average for the last 20 days is -16.50% for NTLA’s stock, with a simple moving average of -31.61% for the last 200 days.
Analysts’ Opinion of NTLA
Many brokerage firms have already submitted their reports for NTLA stocks, with Goldman repeating the rating for NTLA by listing it as a “Neutral.” The predicted price for NTLA in the upcoming period, according to Goldman is $32 based on the research report published on February 23, 2024 of the current year 2024.
Canaccord Genuity gave a rating of “Buy” to NTLA, setting the target price at $66 in the report published on April 13th of the previous year.
NTLA Trading at -21.76% from the 50-Day Moving Average
After a stumble in the market that brought NTLA to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -54.72% of loss for the given period.
Volatility was left at 4.23%, however, over the last 30 days, the volatility rate increased by 4.82%, as shares sank -22.19% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -13.45% lower at present.
During the last 5 trading sessions, NTLA fell by -13.83%, which changed the moving average for the period of 200-days by -47.28% in comparison to the 20-day moving average, which settled at $25.44. In addition, Intellia Therapeutics Inc saw -29.49% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at NTLA starting from BASTA JAMES, who sale 2,297 shares at the price of $32.99 back on Mar 04 ’24. After this action, BASTA JAMES now owns 81,571 shares of Intellia Therapeutics Inc, valued at $75,778 using the latest closing price.
Clark Eliana, the EVP, Chief Technical Officer of Intellia Therapeutics Inc, sale 605 shares at $32.99 during a trade that took place back on Mar 04 ’24, which means that Clark Eliana is holding 71,470 shares at $19,959 based on the most recent closing price.
Stock Fundamentals for NTLA
Current profitability levels for the company are sitting at:
- -14.21 for the present operating margin
- 0.75 for the gross margin
The net margin for Intellia Therapeutics Inc stands at -12.97. The total capital return value is set at -0.43. Equity return is now at value -42.10, with -34.11 for asset returns.
Based on Intellia Therapeutics Inc (NTLA), the company’s capital structure generated 0.1 points at debt to capital in total, while cash flow to debt ratio is standing at -3.42.
Currently, EBITDA for the company is -506.21 million with net debt to EBITDA at 0.22. When we switch over and look at the enterprise to sales, we see a ratio of 53.89. The receivables turnover for the company is 1.0for trailing twelve months and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 8.67.
Conclusion
In conclusion, Intellia Therapeutics Inc (NTLA) has had a bad performance lately. Opinion on the stock among analysts is mixed, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
